Stifel Upgrades Vitae Pharmaceuticals (VTAE) to Buy, $15 PT
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall Street ends sharply higher as Waller remarks ease rate hike fears
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Vitae Pharmaceuticals (VTAE) PT Raised to $23 at Wedbush
March 18, 2016 6:42 AM EDTWedbush analyst Liana Moussatos reiterated an Outperform rating and raised her price target on Vitae Pharmaceuticals (NASDAQ: VTAE) to $23.00 (from $20.00) after proof-of-concept for RAR-Related Orphan Receptor -t ( ROR t) inhibition was achieved, in their view.
Moussatos commented: "The randomized, double blind multiple ascending dose (MAD) Part II trial tested once-daily, orally-dosed... More
JMP Securities Upgrades Vitae Pharmaceuticals (VTAE) to Market Outperform
March 17, 2016 9:33 AM EDTJMP Securities upgraded Vitae Pharmaceuticals (NASDAQ: VTAE) from Market Perform to Market Outperform.
For an analyst ratings summary and ratings history on Vitae Pharmaceuticals click here. For more ratings news on Vitae Pharmaceuticals click here.
Shares of Vitae Pharmaceuticals closed at $4.11 yesterday.
... MoreVitae Pharma (VTAE) Announces Statistically Significant Data from VTP-43742 Phase 2a PoC Trial in Psoriatic Patients
March 16, 2016 4:06 PM EDTVitae Pharmaceuticals, Inc. (Nasdaq: VTAE) announced positive top-line results from its Phase 2a proof-of-concept clinical trial of VTP-43742 in psoriatic patients. VTP-43742 is Vitae's wholly owned, first-in-class, orally active RORt inhibitor with the potential to transform the treatment of multiple autoimmune disorders, including... More
